Literature DB >> 16103093

Signaling through IFN regulatory factor-5 sensitizes p53-deficient tumors to DNA damage-induced apoptosis and cell death.

Guodong Hu1, Margo E Mancl, Betsy J Barnes.   

Abstract

Human IFN regulatory factor-5 (IRF-5) is a candidate tumor suppressor gene that mediates cell arrest, apoptosis, and immune activation. Here we show that ectopic IRF-5 sensitizes p53-proficient and p53-deficient colon cancer cells to DNA damage-induced apoptosis. The combination IFN-beta and irinotecan (CPT-11) cooperatively inhibits cell growth and IRF-5 synergizes with it to further promote apoptosis. The synergism is due to IRF-5 signaling since a striking defect in apoptosis and cell death was observed in IRF-5-deficient cells, which correlated well with a reduction in DNA damage-induced cellular events. Components of this IRF-5 signaling pathway are investigated including a mechanism for DNA damage-induced IRF-5 activation. Thus, IRF-5-regulated pathways may serve as a target for cancer therapeutics.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16103093     DOI: 10.1158/0008-5472.CAN-05-0583

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  52 in total

1.  Genetic variants and disease-associated factors contribute to enhanced interferon regulatory factor 5 expression in blood cells of patients with systemic lupus erythematosus.

Authors:  Di Feng; Rivka C Stone; Maija-Leena Eloranta; Niquiche Sangster-Guity; Gunnel Nordmark; Snaevar Sigurdsson; Chuan Wang; Gunnar Alm; Ann-Christine Syvänen; Lars Rönnblom; Betsy J Barnes
Journal:  Arthritis Rheum       Date:  2010-02

2.  Dual functions of interferon regulatory factors 7C in Epstein-Barr virus-mediated transformation of human B lymphocytes.

Authors:  Yong Zhao; Dongsheng Xu; Yanjun Jiang; Luwen Zhang
Journal:  PLoS One       Date:  2010-03-04       Impact factor: 3.240

Review 3.  Uncovering the immunotherapeutic cycle initiated by p19Arf and interferon-β gene transfer to cancer cells: An inducer of immunogenic cell death.

Authors:  Ruan F V Medrano; Aline Hunger; João P P Catani; Bryan E Strauss
Journal:  Oncoimmunology       Date:  2017-05-19       Impact factor: 8.110

4.  The COP9 signalosome interacts with and regulates interferon regulatory factor 5 protein stability.

Authors:  Justyna Korczeniewska; Betsy J Barnes
Journal:  Mol Cell Biol       Date:  2012-12-28       Impact factor: 4.272

5.  Interferon regulatory factor 5 activation in monocytes of systemic lupus erythematosus patients is triggered by circulating autoantigens independent of type I interferons.

Authors:  Rivka C Stone; Di Feng; Jing Deng; Sukhwinder Singh; Lisong Yang; Patricia Fitzgerald-Bocarsly; Maija-Leena Eloranta; Lars Rönnblom; Betsy J Barnes
Journal:  Arthritis Rheum       Date:  2012-03

6.  Interferon regulatory factor 6 promotes cell cycle arrest and is regulated by the proteasome in a cell cycle-dependent manner.

Authors:  Caleb M Bailey; Daniel E Abbott; Naira V Margaryan; Zhila Khalkhali-Ellis; Mary J C Hendrix
Journal:  Mol Cell Biol       Date:  2008-01-22       Impact factor: 4.272

Review 7.  The innate immune system in SLE: type I interferons and dendritic cells.

Authors:  L Rönnblom; V Pascual
Journal:  Lupus       Date:  2008-05       Impact factor: 2.911

8.  Interferon regulatory factor 4 is involved in Epstein-Barr virus-mediated transformation of human B lymphocytes.

Authors:  Dongsheng Xu; Lingjun Zhao; Luis Del Valle; Judith Miklossy; Luwen Zhang
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

9.  Functional analysis of a dominant negative mutation of interferon regulatory factor 5.

Authors:  Long Yang; Tiejun Zhao; Xiaoliu Shi; Peyman Nakhaei; Yunling Wang; Qiang Sun; John Hiscott; Rongtuan Lin
Journal:  PLoS One       Date:  2009-05-11       Impact factor: 3.240

10.  Development of monoclonal antibodies against human IRF-5 and their use in identifying the binding of IRF-5 to nuclear import proteins karyopherin-alpha1 and -beta1.

Authors:  Soo-In Yeon; Ju Ho Youn; Mi Hwa Lim; Hye Ja Lee; Young Mok Kim; Ji Eun Choi; Jae Myun Lee; Jeon-Soo Shin
Journal:  Yonsei Med J       Date:  2008-12-31       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.